Varma Mutual Pension Insurance Co Reduces Position in Elevance Health, Inc. $ELV
by Jessica Moore · The Cerbat GemVarma Mutual Pension Insurance Co trimmed its holdings in Elevance Health, Inc. (NYSE:ELV – Free Report) by 12.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 39,882 shares of the company’s stock after selling 5,900 shares during the quarter. Varma Mutual Pension Insurance Co’s holdings in Elevance Health were worth $13,981,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Physician Wealth Advisors Inc. raised its position in shares of Elevance Health by 331.6% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after purchasing an additional 63 shares during the last quarter. Rossby Financial LCC grew its stake in Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock valued at $28,000 after acquiring an additional 44 shares in the last quarter. Activest Wealth Management grew its stake in Elevance Health by 66.7% during the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after acquiring an additional 34 shares in the last quarter. Motco grew its stake in Elevance Health by 334.8% during the 3rd quarter. Motco now owns 100 shares of the company’s stock valued at $32,000 after acquiring an additional 77 shares in the last quarter. Finally, ORG Partners LLC grew its stake in Elevance Health by 120.4% during the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after acquiring an additional 59 shares in the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.
Elevance Health Stock Performance
NYSE:ELV opened at $371.61 on Tuesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. The stock has a market capitalization of $80.70 billion, a P/E ratio of 15.81, a PEG ratio of 2.12 and a beta of 0.66. The company has a 50 day moving average price of $310.69 and a 200 day moving average price of $331.64. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $424.24.
Elevance Health (NYSE:ELV – Get Free Report) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. The firm had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The firm’s quarterly revenue was up 1.5% on a year-over-year basis. During the same quarter last year, the company posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Equities research analysts forecast that Elevance Health, Inc. will post 26.79 EPS for the current year.
Elevance Health Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be given a dividend of $1.72 per share. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.9%. Elevance Health’s dividend payout ratio (DPR) is presently 29.26%.
Wall Street Analyst Weigh In
A number of research firms have weighed in on ELV. Mizuho lowered their price objective on Elevance Health from $413.00 to $350.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 11th. Royal Bank Of Canada lowered Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price objective on the stock. in a research note on Tuesday, February 3rd. Wolfe Research set a $425.00 price objective on Elevance Health and gave the stock an “outperform” rating in a research note on Thursday, January 8th. Truist Financial lowered their price objective on Elevance Health from $390.00 to $375.00 and set a “buy” rating on the stock in a research note on Monday, April 13th. Finally, JPMorgan Chase & Co. boosted their price objective on Elevance Health from $397.00 to $411.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 28th. Thirteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $384.58.
Check Out Our Latest Stock Analysis on ELV
Elevance Health Company Profile
Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.
Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.
Featured Stories
Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).